Investors and stakeholders invited to attend in person in New York City or via live webcast on Monday, November 10th at 8:00 a.m. ET LAWRENCEVILLE, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, will host an R&D Day on Monday, November 10, 2025 at 8:00 a.m. ET in New York City featuring in-depth discussions with experts including principal investigators leading the Phase 3 OVATION 3 clinical trial and ...

Core Insights - Altimmune, Inc. announced significant results from the IMPACT Phase 2b trial of pemvidutide, demonstrating reductions in liver fibrosis and improvements in non-invasive tests compared to placebo at 24 weeks [1][2][5] Group 1: Trial Results - The AI-based pathology tool Liver Explore™ showed significant reductions in early, advanced, and total liver fibrosis areas with pemvidutide treatment compared to placebo at 24 weeks [2] - In the trial, 58% of patients achieved MASH resolution, indicating the efficacy of the glucagon/GLP-1 balanced approach in pemvidutide [5] - Statistically significant reductions in total liver fibrosis were observed, with 31% of patients in the 1.8 mg group achieving a ≥ 60% reduction compared to 8% in the placebo group [7] Group 2: Study Design - The IMPACT Phase 2b trial was a randomized, placebo-controlled, double-blind study involving 212 participants with biopsy-confirmed MASH and fibrosis stages F2 or F3 [6] - Participants were randomized to receive weekly subcutaneous doses of pemvidutide at either 1.2 mg, 1.8 mg, or placebo for 48 weeks, with key efficacy endpoints measured at 24 weeks [6] Group 3: Mechanism and Future Outlook - Pemvidutide is a novel investigational peptide with dual receptor agonist activity targeting both glucagon and GLP-1, aimed at treating MASH, AUD, and ALD [8] - The FDA has granted Fast Track designations for pemvidutide in treating MASH and AUD, highlighting the unmet medical need in these areas [9] - The final readout of the ongoing 48-week IMPACT trial is anticipated in the fourth quarter of 2025, which will include longer-term data on non-invasive tests and weight loss [9]

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ETTD Cowen Immunology & Inflammation Summit on Thursday, November 13 at 9:30 am ET8th Annual Evercore Healthcare Conference on Tuesday, December 2 at 3:00 pm ET Live webcasts of the presentations will be available on the "Events & Pres ...

Core Insights - Conduent Incorporated reported its Q3 2025 financial results, highlighting a 5.0% decline in revenue year-over-year, with adjusted revenue down 1.8% [2][3][4] - The company achieved a significant increase in adjusted EBITDA, which rose by 25.0% year-over-year, reflecting improved operational efficiency [3][8] - New business signings remained consistent year-over-year, particularly in the Public Sector, despite challenges such as government funding cycles and a federal government shutdown [3][4] Financial Performance - Revenue for Q3 2025 was $767 million, compared to $807 million in Q3 2024 [3][4] - Adjusted EBITDA for the quarter was $40 million, with an adjusted EBITDA margin of 5.2%, up from 4.1% in the prior year [3][8] - GAAP net loss for the quarter was $(46) million, a significant decrease from a net income of $123 million in the same period last year [3][4] Operational Highlights - The company maintained a cash balance of $264 million and had $198 million in unused capacity under its renewed credit facility [5] - Conduent repurchased approximately 4.7 million shares of common stock during the quarter [5] - The company has achieved 87% of its $1 billion capital allocation target through portfolio rationalization efforts [3][4] Future Outlook - For FY 2025, Conduent projects adjusted revenue between $3,050 million and $3,100 million, with an adjusted EBITDA margin target of 5.0% to 5.5% [9] - The company continues to focus on cash generation and expanding its pipeline opportunities, particularly within its existing client base [3][4]

WEST PALM BEACH, Fla., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Dycom Industries, Inc. (NYSE: DY) will host a conference call to discuss fiscal 2026 third quarter results on Wednesday, November 19, 2025, at 9:00 a.m. ET. Dycom will issue a press release reporting its results earlier that morning. Interested parties may participate in the question and answer session of the conference call by registering at https://register-conf.media-server.com/register/BI9a839022ad944fb09c33dfa69ba71132. Upon registration, partici ...

The Lawson Target Exhibits All Five Key Elements for a Potential Natural Hydrogen Accumulation Including Source Rocks, Migration Pathways, Reservoirs, Seals and Traps, Along With a Defined Four-Way Structural Closure MAX Power Saskatchewan Natural Hydrogen Documentary Videohttps://www.maxpowermining.com/NaturalHydrogen-NewEra/ SASKATOON, Saskatchewan, Nov. 07, 2025 (GLOBE NEWSWIRE) -- MAX Power Mining Corp. (CSE: MAXX; OTC: MAXXF; Frankfurt: 89N) (“MAX Power” or the “Company”) is pleased to announce that it ...

– Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation – SOUTH SAN FRANCISCO, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, today announced Phase 1b clinical data for its next-generation investigational capsid assembly modulator (CAM) ABI-4334 featured in a late-breaki ...

The net result as of September 30, 2025 improved by $1.1M compared to September 2024, following termination of a Convertible Bonds financing facility with Nice&Green CNS(Vafidemstat) Received feedback from the FDA on Phase III PORTICO-2 trial in BPD; Company to revise protocol and resubmitReinforcing company’s clinical, strategy and regulatory teamsExpansion of ongoing Phase IIb in schizophrenia into other EU countries continuesPreparations continue for new Phase II trial in aggression in Autism Spectrum Di ...

Single ascending dose data show IMC-I109V has manageable safety profile and antiviral activity IMC-I109V is a bispecific T cell receptor targeting a peptide derived from HBsAg that is presented by HLA-A*02:01 on the surface of infected hepatocytes (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 7, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medici ...

Proceeds of up to $10 million, consisting of $3 million at closing, $1 million upon availability of commercial product, and up to $6 million in sales-related milestone payments. Transaction further bolsters our cash position, which is expected to fund Biofrontera to profitability.Proceeds will support the growth of Biofrontera’s commercial photodynamic therapy (PDT) platform, and expansion of Ameluz® into additional indications. WOBURN, Mass., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI ...